The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment

A preliminary randomized double-blind placebo-controlled study

Chih Chiang Chiu, Kuan Pin Su, Tsung Chi Cheng, Hsing Cheng Liu, Ching Jui Chang, Michael E. Dewey, Robert Stewart, Shih Yi Huang

Research output: Contribution to journalArticle

218 Citations (Scopus)

Abstract

A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8  g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p = 0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p = 0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p = 0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment.

Original languageEnglish
Pages (from-to)1538-1544
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume32
Issue number6
DOIs
Publication statusPublished - Aug 1 2008

Fingerprint

Omega-3 Fatty Acids
Unsaturated Fatty Acids
Alzheimer Disease
Placebos
Eicosapentaenoic Acid
Sample Size
Cognition
Interviews
Diet
Membranes
Cognitive Dysfunction
Therapeutics
Population

Keywords

  • Alzheimer's disease
  • Cognition
  • Fish oil
  • Mild cognitive impairment
  • Polyunsaturated fatty acids

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment : A preliminary randomized double-blind placebo-controlled study. / Chiu, Chih Chiang; Su, Kuan Pin; Cheng, Tsung Chi; Liu, Hsing Cheng; Chang, Ching Jui; Dewey, Michael E.; Stewart, Robert; Huang, Shih Yi.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 6, 01.08.2008, p. 1538-1544.

Research output: Contribution to journalArticle

Chiu, Chih Chiang ; Su, Kuan Pin ; Cheng, Tsung Chi ; Liu, Hsing Cheng ; Chang, Ching Jui ; Dewey, Michael E. ; Stewart, Robert ; Huang, Shih Yi. / The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment : A preliminary randomized double-blind placebo-controlled study. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 ; Vol. 32, No. 6. pp. 1538-1544.
@article{34a3fc1671fa43e1a949c3e852759f8a,
title = "The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study",
abstract = "A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8  g/day or placebo (olive oil). The data of 35 (76{\%}) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p = 0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p = 0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p = 0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment.",
keywords = "Alzheimer's disease, Cognition, Fish oil, Mild cognitive impairment, Polyunsaturated fatty acids",
author = "Chiu, {Chih Chiang} and Su, {Kuan Pin} and Cheng, {Tsung Chi} and Liu, {Hsing Cheng} and Chang, {Ching Jui} and Dewey, {Michael E.} and Robert Stewart and Huang, {Shih Yi}",
year = "2008",
month = "8",
day = "1",
doi = "10.1016/j.pnpbp.2008.05.015",
language = "English",
volume = "32",
pages = "1538--1544",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment

T2 - A preliminary randomized double-blind placebo-controlled study

AU - Chiu, Chih Chiang

AU - Su, Kuan Pin

AU - Cheng, Tsung Chi

AU - Liu, Hsing Cheng

AU - Chang, Ching Jui

AU - Dewey, Michael E.

AU - Stewart, Robert

AU - Huang, Shih Yi

PY - 2008/8/1

Y1 - 2008/8/1

N2 - A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8  g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p = 0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p = 0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p = 0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment.

AB - A 24-week, randomized, double-blind placebo-controlled study was carried out to test the feasibility of using omega-3 polyunsaturated fatty acids (PUFAs) monotherapy in people with cognitive impairment and to explore its effects on cognitive function and general clinical condition in these participants. Twenty three participants with mild or moderate Alzheimer's disease and twenty three with mild cognitive impairment were randomized to receive omega-3 PUFAs 1.8  g/day or placebo (olive oil). The data of 35 (76%) participants with at least one post-treatment visit was analyzed. There were no severe adverse effects in either group and it suggests that omega-3 PUFAs were well tolerable in this population. The treatment group showed better improvement on the Clinician's Interview-Based Impression of Change Scale (CIBIC-plus) than those in the placebo group over the 24 week follow-up (p = 0.008). There was no significant difference in the cognitive portion of the Alzheimer's Disease Assessment Scale (ADAS-cog) change during follow-up in these two groups. However, the omega-3 fatty acids group showed significant improvement in ADAS-cog compared to the placebo group in participants with mild cognitive impairment (p = 0.03), which was not observed in those with Alzheimer's disease. Higher proportions of eicosapentaenoic acid on RBC membranes were also associated with better cognitive outcome (p = 0.003). Further studies should be considered with a larger-sample size, diet registration, higher dosages, comparisons between different combinations of PUFAs, and greater homogeneity of participants, especially those with mild Alzheimer's disease and mild cognitive impairment.

KW - Alzheimer's disease

KW - Cognition

KW - Fish oil

KW - Mild cognitive impairment

KW - Polyunsaturated fatty acids

UR - http://www.scopus.com/inward/record.url?scp=47749114025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749114025&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2008.05.015

DO - 10.1016/j.pnpbp.2008.05.015

M3 - Article

VL - 32

SP - 1538

EP - 1544

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 6

ER -